Author:
Liang Boyun,Xiang Tiandan,Wang Hua,Li Ziwei,Quan Xufeng,Feng Xuemei,Li Sumeng,Lu Sihong,Fan Lei,Xu Ling,Wang Tong,Wang Xiaoyan,Zhu Bin,Wang Junzhong,Yang Dongliang,Liu Jia,Zheng Xin
Abstract
COVID-19, caused by SARS-CoV-2, has resulted in hundreds of millions of infections and millions of deaths worldwide. Preliminary results exhibited excellent efficacy of SARS-CoV-2 vaccine in preventing hospitalization and severe disease. However, data on inactivated vaccine-induced immune responses of naturally infected patients are limited. Here, we characterized SARS-CoV-2 RBD-specific IgG (anti-S-RBD IgG) and neutralizing antibodies (NAbs) against SARS-CoV-2 wild type and variants of concerns (VOCs), as well as RBD-specific IgG-secreting B cells and antigen-specific T cells respectively in 51 SARS-CoV-2 recovered subjects and 63 healthy individuals. In SARS-CoV-2 recovered patients, a single dose vaccine is sufficient to reactivate robust anti-S-RBD IgG and NAbs. The neutralizing capacity against VOCs increased significantly post-vaccination no matter healthy individuals or SARS-CoV-2 recovered patients. In addition, RBD-specific IgG-secreting B cells in SARS-CoV-2 recovered patients were significantly higher than that in healthy vaccine recipients. After the vaccine booster, the frequencies of specific IFN-γ+ CD4+ T cell, IL-2+ CD4+ T cell, and TNF-α+ CD4+ T cell responses were significantly increased in SARS-CoV-2 recovered patients. Our data highlighted the safety and utility of SARS-CoV-2 inactivated vaccine and demonstrated that robust humoral and cellular immune response can be reactivated by one-dose inactivated vaccine in SARS-CoV-2 recovered patients.
Subject
Immunology,Immunology and Allergy
Reference33 articles.
1. SARS-CoV-2 variants, spike mutations and immune escape;Harvey;Nat Rev Microbiol,2021
2. The biological and clinical significance of emerging SARS-CoV-2 variants;Tao;Nat Rev Genet,2021
3. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost;Ai;Emerg Microbes Infect,2022
4. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine;Polack;N Engl J Med,2020
5. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Zhang;Lancet Infect Dis,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献